GUCY2C and breast cancer: Eight-year breast cancer survival for pseudorandomized groups were 98.29% (CI:97.98–98.56) for GCC, 98.08% (CI:97.69–98.41) for AS1, and 91.81% (90.54–92.91) for AS2.